Grace Therapeutics Inc. has released a corporate presentation detailing the development of GTx-104, a novel intravenous form of nimodipine. This treatment is positioned to address significant unmet needs in the management of aneurysmal Subarachnoid Hemorrhage (aSAH) by potentially displacing the current oral standard of care. The pivotal Phase 3 STRIVE-ON safety trial for GTx-104 has successfully met its primary endpoint, showing clinical benefits over oral nimodipine. With Orphan Drug Status, the drug is set to receive seven-year market exclusivity, complemented by multi-layered intellectual property protection. A New Drug Application was submitted in June 2025. You can access the full presentation through the link below.